InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (12 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
12
T+90 hit rate
0%
T+90 mean return
-14.5%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Anish Bhatnagar, Chairman & CEO. Director active across 1 company, notably Soleno Therapeutics INC. In total, 20 reports have been logged. Breakdown: 1 buy · 12 sells. Total volume traded: €8.5m. Activity tracked since 21 January 2022. The latest transaction was filed on 21 January 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Anish Bhatnagar
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations20 total
114,200 shares0Common StockSEC:0001614821-26-000001:0
7,620 shares@ US$49.953.7% of flowCommon StockSEC:0001614821-25-000005:0
14,183 shares@ US$65.969110.2% of flowCommon StockSEC:0001415889-25-009290:0
53,900 shares0Common StockSEC:0001415889-25-001932:0
10,077 shares@ US$45.36565.2% of flowCommon StockSEC:0001415889-25-000953:0
19,413 shares@ US$49.335810.2% of flowCommon StockSEC:0001415889-24-024658:0
30,262 shares@ US$47.192615.1% of flowCommon StockSEC:0001415889-24-022648:0
32,789 shares@ US$45.476716.0% of flowCommon StockSEC:0001415889-24-020943:0
850,000 shares0Common StockSEC:0001415889-24-019807:0
4,198 shares@ US$41.22171.9% of flowCommon StockSEC:0001415889-24-019266:0
11,383 shares@ US$41.12275.1% of flowCommon StockSEC:0001415889-24-010241:0
2,527 shares@ US$48.301.3% of flowCommon StockSEC:0001415889-24-001925:0
150,000 shares0Common StockSEC:0001209191-24-001174:0
51,205 shares@ US$35.259819.7% of flowCommon StockSEC:0001209191-23-058577:0
4,000 shares@ US$4.500.2% of flowCommon StockSEC:0001209191-23-058575:0
27,716 shares@ US$28.65198.5% of flowCommon StockSEC:0001209191-23-057318:0
21,220 shares@ US$27.02626.2% of flowCommon StockSEC:0001209191-23-057034:0
160,602 shares0Common StockSEC:0001209191-23-032691:0
60,000 sharesCommon StockSEC:0000899243-22-013312:0
Canonical exit: 29 Jun 2022 (T+90)
39,033 shares@ US$0.3730.0005% mcap50.0% of flowCommon StockSEC:0000899243-22-003186:0
20 of 20 declarations
About Anish Bhatnagar
Anish Bhatnagar is the Chief Executive Officer of Soleno Therapeutics Inc. He leads the company in developing innovative treatments for rare diseases. Under his leadership, Soleno Therapeutics is committed to improving patients' lives through advanced therapeutic solutions and cutting-edge research.
